Muscari Antonio, Falcone Roberta, Recinella Guerino, Faccioli Luca, Forti Paola, Pastore Trossello Marco, Puddu Giovanni M, Spinardi Luca, Zoli Marco
Stroke Unit, Medical Department of Continuity of Care and Disability, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy.
Diabetol Metab Syndr. 2022 Aug 29;14(1):126. doi: 10.1186/s13098-022-00896-9.
Hyperglycemic non-diabetic stroke patients have a worse prognosis than both normoglycemic and diabetic patients. Aim of this study was to assess whether hyperglycemia is an aggravating factor or just an epiphenomenon of most severe strokes.
In this retrospective study, 1219 ischemic or hemorrhagic stroke patients (73.7 ± 13.1 years) were divided into 4 groups: 0 = non-hyperglycemic non-diabetic, 1 = hyperglycemic non-diabetic, 2 = non-hyperglycemic diabetic and 3 = hyperglycemic diabetic. Hyperglycemia was defined as fasting blood glucose ≥ 126 mg/dl (≥ 7 mmol/l) measured the morning after admission, while the diagnosis of diabetes was based on a history of diabetes mellitus or on a glycated hemoglobin ≥ 6.5% (≥ 48 mmol/mol), independently of blood glucose levels. All diabetic patients, except 3, had Type 2 diabetes. The 4 groups were compared according to clinical history, stroke severity indicators, acute phase markers and main short term stroke outcomes (modified Rankin scale ≥ 3, death, cerebral edema, hemorrhagic transformation of ischemic lesions, fever, oxygen administration, pneumonia, sepsis, urinary infection and heart failure).
Group 1 patients had more severe strokes, with larger cerebral lesions and higher inflammatory markers, compared to the other groups. They also had a high prevalence of atrial fibrillation, prediabetes, previous stroke and previous arterial revascularizations. In this group, the highest frequencies of cerebral edema, hemorrhagic transformation, pneumonia and oxygen administration were obtained. The prevalence of dependency at discharge and in-hospital mortality were equally high in Group 1 and Group 3. However, in multivariate analyses including stroke severity, cerebral lesion diameter, leukocytes and C-reactive protein, Group 1 was only independently associated with hemorrhagic transformation (OR 2.01, 95% CI 0.99-4.07), while Group 3 was independently associated with mortality (OR 2.19, 95% CI 1.32-3.64) and disability (OR 1.70, 95% CI 1.01-2.88).
Hyperglycemic non-diabetic stroke patients had a worse prognosis than non-hyperglycemic or diabetic patients, but this group was not independently associated with mortality or disability when size, severity and inflammatory component of the stroke were accounted for.
血糖升高的非糖尿病性卒中患者的预后比血糖正常和糖尿病性卒中患者更差。本研究的目的是评估高血糖是一个加重因素还是仅仅是最严重卒中的一种附带现象。
在这项回顾性研究中,1219例缺血性或出血性卒中患者(73.7±13.1岁)被分为4组:0组=非高血糖非糖尿病组,1组=高血糖非糖尿病组,2组=非高血糖糖尿病组,3组=高血糖糖尿病组。高血糖定义为入院后次日早晨测得的空腹血糖≥126mg/dl(≥7mmol/l),而糖尿病的诊断基于糖尿病病史或糖化血红蛋白≥6.5%(≥48mmol/mol),与血糖水平无关。除3例患者外,所有糖尿病患者均为2型糖尿病。根据临床病史、卒中严重程度指标、急性期标志物和主要短期卒中结局(改良Rankin量表≥3分、死亡、脑水肿、缺血性病变的出血转化、发热、吸氧、肺炎、脓毒症、泌尿系统感染和心力衰竭)对4组进行比较。
与其他组相比,1组患者的卒中更严重,脑损伤更大,炎症标志物更高。他们还具有较高的房颤、糖尿病前期、既往卒中史和既往动脉血运重建患病率。在该组中,脑水肿、出血转化、肺炎和吸氧的发生率最高。1组和3组出院时的依赖率和院内死亡率同样高。然而,在包括卒中严重程度、脑损伤直径、白细胞和C反应蛋白的多变量分析中,1组仅与出血转化独立相关(比值比2.01,95%可信区间0.99-4.07),而3组与死亡率(比值比2.19,95%可信区间1.32-3.64)和残疾(比值比1.70,95%可信区间1.01-2.88)独立相关。
血糖升高的非糖尿病性卒中患者的预后比血糖正常或糖尿病性卒中患者更差,但在考虑卒中的大小、严重程度和炎症成分时,该组与死亡率或残疾并无独立相关性。